Introducing Our New Principal Investigator: Dr. Marcus Klingenberg
May 6, 2025
Introducing Our New Principal Investigator: Dr. Marcus Klingenberg
RegenMed is proud to announce that Dr. Marcus Klingenberg will be acting as a Principal Investigator for four separate Physicians-Owned Circles in the field of micronized adipose tissue therapies for musculoskeletal indications. Dr. Klingenberg is an internationally recognized orthopedic surgeon; patients from throughout Europe travel to the BetaKlinik which he co-founded in 2008 in Bonn, Germany.
The four separate Observational Protocols will cover MFAT treatment for unilateral knee cases, bilateral knee cases, unilateral hip cases, and bilateral hip cases. They will generate statistically and clinically significant longitudinal datasets, including specific devices utilized, within only a few months. Those proprietary data sets, and resulting license fees, will be owned 85% by participating POC members. RegenMed is already in preliminary discussions for pre-licensing arrangements with MFAT device manufacturers.
Dr. Klingenberg’s Observational Protocols will be published shortly on RegenMed’s POC Library Page. Qualifying clinicians interested in joining one more of those POC’s are encouraged to apply.
Introducing Our New Principal Investigator: Dr. Marcus Klingenberg
May 6, 2025
RegenMed is proud to announce that Dr. Marcus Klingenberg will be acting as a Principal Investigator for four separate Physicians-Owned Circles in the field of micronized adipose tissue therapies for musculoskeletal indications. Dr. Klingenberg is an internationally recognized orthopedic surgeon; patients from throughout Europe travel to the BetaKlinik which he co-founded in 2008 in Bonn, Germany.
The four separate Observational Protocols will cover MFAT treatment for unilateral knee cases, bilateral knee cases, unilateral hip cases, and bilateral hip cases. They will generate statistically and clinically significant longitudinal datasets, including specific devices utilized, within only a few months. Those proprietary data sets, and resulting license fees, will be owned 85% by participating POC members. RegenMed is already in preliminary discussions for pre-licensing arrangements with MFAT device manufacturers.
Dr. Klingenberg’s Observational Protocols will be published shortly on RegenMed’s POC Library Page. Qualifying clinicians interested in joining one more of those POC’s are encouraged to apply.
